Trials / Not Yet Recruiting
Not Yet RecruitingNCT04485156
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin to 3 Months After Culture Conversion (Hi-DoRi-3): A Phase 3, Multicenter, Randomized, Open-label, Clinical Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 926 (estimated)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the effectiveness and safety of the regimen including high dose rifampicin for individualized duration (3 months after Culture Conversion) for the treatment of drug-sensitive pulmonary tuberculosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | High-dose rifampicin | 30mg/kg |
| DRUG | Isoniazid | 300mg |
| DRUG | Pyrazinamide | 20-30mg/kg |
| DRUG | Ethambutol | 15-20mg/kg |
| DRUG | Rifampicin | 10mg/kg |
Timeline
- Start date
- 2020-09-01
- Primary completion
- 2025-08-01
- Completion
- 2026-12-01
- First posted
- 2020-07-24
- Last updated
- 2020-07-24
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04485156. Inclusion in this directory is not an endorsement.